This inventor holds 4 USPTO granted patents and 3 published patent applications and 4 EPO patents. Top assignees: University of Miami, Johns Hopkins University. Active years: 2016-2026.
Location History:
- Abano Terme, IT (2016 - 2020)
- Verona, IT (2022)
Company Filing History:
Years Active: 2016-2026
Title: Vincenzo Bronte: Innovator in Nanoparticle Technology
Introduction
Vincenzo Bronte is a notable inventor based in Abano Terme, Italy. He has made significant contributions to the field of nanoparticle technology, holding a total of three patents. His work focuses on the development of innovative methods for delivering nucleic acids to cells, which has important implications for medical research and treatment.
Latest Patents
Bronte's latest patents include groundbreaking advancements in nanoparticle conjugates. One of his patents describes nanoparticle-based compositions, kits, and methods for delivering nucleic acids to a cell. Another patent focuses on similar compositions and methods specifically designed for delivering nucleic acids to myeloid cells. These innovations highlight his commitment to enhancing the efficacy of genetic material delivery in therapeutic applications.
Career Highlights
Throughout his career, Vincenzo Bronte has collaborated with prestigious institutions such as the University of Miami and Johns Hopkins University. His work in these esteemed organizations has allowed him to further his research and contribute to the scientific community. His expertise in nanoparticle technology has positioned him as a leading figure in this innovative field.
Collaborations
Some of Bronte's notable coworkers include Paolo Serafini and Jennifer Vella. Their collaborative efforts have contributed to the advancement of research in nanoparticle applications and have fostered a productive environment for innovation.
Conclusion
Vincenzo Bronte's contributions to nanoparticle technology and his dedication to advancing medical research make him a significant figure in the field of innovation. His patents and collaborations reflect his commitment to improving the delivery of nucleic acids, paving the way for future advancements in therapeutic applications.